The regulatory members of the International Council on Harmonization have endorsed additional Q11 guidance that answers some questions on when industry must begin applying good manufacturing practice controls to active pharmaceutical ingredient manufacturing processes.
The US, the EU, Japan and other regulatory members will seek comment on the draft Q11 Q&A guidance in their...